Hansoh Pharma (China)

Recent papers from Hansoh Pharma (China)

1. Acceptable GPCR–nanobody predictions can mask errors in confidence ranking2026
2. Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
3. Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter StudyInternational Journal of Cancer · 2026
4. A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasisJournal of the European Academy of Dermatology and Venereology · 2026
5. Rapid Quantification of Low-Level Crystalline Impurities in Dalmelitinib Mesylate Using NIR Spectroscopy and Chemometric ModelingSeparations · 2026
6. Phase 1 randomized trial of HS-10353, a novel GABA(A) positive allosteric modulator for treatment of major depressive disorderBMC Medicine · 2026
7. Study on the Whole-Process Hysteresis Model of Straight Mortise-Tenon Joint in Timber FrameKSCE Journal of Civil Engineering · 2026
8. Effect of Polyethylene Glycol Loxenatide Treatment on Body Weight in Patients With Type 2 Diabetes With Different Body Mass Index: A Retrospective Real‐World StudyInternational Journal of Endocrinology · 2026
9. Abstract CT038: Combination of risvutatug rezetecan and adebrelimab in previously treated advanced nsq-NSCLC without actionable genomic alterations: Results from ARTEMIS-101, a phase 1 studyCancer Research · 2026
10. Abstract CT302: The safety, tolerability, and efficacy of HS-10504 in patients with EGFR mutation-positive locally advanced or metastatic NSCLC: Initial results from a first-in-human phase 1 studyCancer Research · 2026
11. Abstract 7097: Non-clinical characterization of GSK5764227, a novel B7-H3-directed antibody-drug conjugate (ADC)Cancer Research · 2026
12. Abstract 4575: Non-clinical characterization of Mocertatug Rezetecan (GSK5733584), a novel B7-H4-directed antibody-drug conjugateCancer Research · 2026
13. HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 StudyDermatology and Therapy · 2026
14. A Comparative Study of Porcine and Ovine Derived Defibrotide: Coagulation Profiles, Molecular Characteristics, and DNA ContentClinical and Applied Thrombosis/Hemostasis · 2026
15. 31P HS-10241 combined with aumolertinib in EGFR-TKIs pretreated EGFR-mutant and MET-amplified advanced NSCLC: A phase Ib studyESMO Open · 2026
16. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trialCancer Cell · 2026
17. ARTEMIS-003: A phase 2 study of HS-20093 (GSK5764227) in patients with metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology · 2026
18. sB7-H3 as a prognostic biomarker in osteosarcoma: insights into clinical outcomesScientific Reports · 2026
19. Coupling Supercritical Fluid Chromatography with Internal Standard Corrected Quantitative NMR for Rapid and Accurate Purity AssessmentAnalytical Chemistry · 2025
20. HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancerJournal of Translational Medicine · 2025